Ryzumvi is a drug owned by Famygen Life Sciences Inc. It is protected by 6 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 25, 2039. Details of Ryzumvi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11400077 | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
Oct, 2039
(14 years from now) | Active |
| US11844858 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | Active |
| US9795560 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | Active |
| US11090261 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | Active |
| US10278918 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | Active |
| US10772829 | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ryzumvi's patents.
Latest Legal Activities on Ryzumvi's Patents
Given below is the list of recent legal activities going on the following patents of Ryzumvi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Mar, 2024 | US10772829 |
| Electronic Review Critical | 02 Feb, 2024 | US11844858 |
| Email Notification Critical | 20 Dec, 2023 | US11844858 |
| Recordation of Patent Grant Mailed Critical | 19 Dec, 2023 | US11844858 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Dec, 2023 | US11844858 |
| Recordation of Patent eGrant | 19 Dec, 2023 | US11844858 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844858 |
| Email Notification Critical | 30 Nov, 2023 | US11844858 |
| Issue Notification Mailed Critical | 29 Nov, 2023 | US11844858 |
FDA has granted several exclusivities to Ryzumvi. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ryzumvi, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ryzumvi.
Exclusivity Information
Ryzumvi holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Ryzumvi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2026 |
US patents provide insights into the exclusivity only within the United States, but Ryzumvi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ryzumvi's family patents as well as insights into ongoing legal events on those patents.
Ryzumvi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ryzumvi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 25, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ryzumvi Generic API suppliers:
Phentolamine Mesylate is the generic name for the brand Ryzumvi. 2 different companies have already filed for the generic of Ryzumvi, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Ryzumvi's generic
Alternative Brands for Ryzumvi
Ryzumvi which is used for treating pharmacologically-induced mydriasis., has several other brand drugs using the same active ingredient (Phentolamine Mesylate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Septodont Holding |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Phentolamine Mesylate, Ryzumvi's active ingredient. Check the complete list of approved generic manufacturers for Ryzumvi
About Ryzumvi
Ryzumvi is a drug owned by Famygen Life Sciences Inc. It is used for treating pharmacologically-induced mydriasis. Ryzumvi uses Phentolamine Mesylate as an active ingredient. Ryzumvi was launched by Famygen Life Sci in 2023.
Approval Date:
Ryzumvi was approved by FDA for market use on 25 September, 2023.
Active Ingredient:
Ryzumvi uses Phentolamine Mesylate as the active ingredient. Check out other Drugs and Companies using Phentolamine Mesylate ingredient
Treatment:
Ryzumvi is used for treating pharmacologically-induced mydriasis.
Dosage:
Ryzumvi is available in solution form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.75% BASE | SOLUTION | Prescription | OPHTHALMIC |